Press releases
- Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
- Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Key statistics
On Tuesday, Relmada Therapeutics Inc (4E2:DUS) closed at 3.48, 8.07% above its post-IPO low of 3.22, set on Apr 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.50 |
---|---|
High | 3.50 |
Low | 3.48 |
Bid | 3.50 |
Offer | 3.60 |
Previous close | 3.58 |
Average volume | 111.11 |
---|---|
Shares outstanding | 30.17m |
Free float | 27.75m |
P/E (TTM) | -- |
Market cap | 116.17m USD |
EPS (TTM) | -3.28 USD |
Data delayed at least 15 minutes, as of May 07 2024 18:31 BST.
More ▼